CurifyLabs has raised $14 million in a Series A financing to expand its personalized medicine platform, with proceeds supporting U.S. growth, supply chain expansion, customer support, and product development.
The round was co-led by Sandwater and HealthCap, with participation from Tesi and existing investors including Lifeline Ventures.
Related: Leo Cancer Care raises $65M Series D to scale upright cancer care platform
The Finland- and U.S.-based company’s Compounding System Solution (CSS) combines proprietary software, GMP-manufactured excipient bases, and 3D printing technology to automate the production of personalized medications. The platform is currently used by pharmacies across Europe and in 21 U.S. states to produce customized doses more efficiently than traditional manual compounding.
CEO and founder Charlotta Topelius said:
“We have set a high bar for clinical rigor, product quality, and customer support, and this funding gives us the resources to raise that bar further.”
The funding will also support continued development of the company’s PharmaPrinter Aurum, a 3D pharmaceutical printer designed to compound medications up to nine times faster than manual processes.
